Literature DB >> 8252813

Extracts of wheat gluten activate complement via the alternative pathway.

D J Unsworth1, R Würzner, D L Brown, P J Lachmann.   

Abstract

We studied the ability of wheat gluten and its subfractions to activate complement directly. A sensitive sandwich ELISA employing a monoclonal antibody (MoAb) to a C9 neoepitope exposed in the terminal complement complex (TCC), a functional haemolytic assay for C5b6 generation, and Laurell's electrophoretic method of estimating C3 conversion to C3bi were used. On a weight-for-weight basis, enzyme solubilized Frazer's fraction three of gluten (FIII) produced approximately 75% of the complement activation seen with the potent activator zymosan. By contrast, activation with whole insoluble undigested gluten was very weak and similar to that seen with ovalbumin or beta-lactoglobulin. The results were the same using normal human serum or sera from patients with coeliac disease, dermatitis herpetiformis, or hypogammaglobulinaemia as the complement source. Activation by both zymosan and FIII was blocked in 0.01 M EDTA, but not in 0.01 M EGTA with 0.0025 M magnesium chloride. Zymosan and FIII activated complement in a serum from a patient with an intact alternative pathway but classical pathway haemolytic activity (CH50) of zero. Preferential heat inactivation of the alternative pathway inhibited both zymosan- and FIII-induced activation. Our results confirm that FIII is a strong activator of the alternative pathway. We discuss how gluten enteropathy might be initiated by complement.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252813      PMCID: PMC1534432     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies.

Authors:  R Würzner; M Schulze; L Happe; A Franzke; F A Bieber; M Oppermann; O Götze
Journal:  Complement Inflamm       Date:  1991

2.  Activation of the alternative pathway by gluten. A possible aetiological factor in dermatitis herpetiformis.

Authors:  A Massey; P M Capner; J F Mowbray
Journal:  Immunology       Date:  1977-09       Impact factor: 7.397

3.  Alternate-pathway complement fixation by IgA in the skin in dermatitis herpetiformis.

Authors:  P P Seah; L Fry; M R Mazaheri; J F Mowbray; A V Hoffbrand; E J Holborow
Journal:  Lancet       Date:  1973-07       Impact factor: 79.321

4.  Studies on the significance of the R1 anti-reticulin antibody associated with gluten sensitivity.

Authors:  D J Unsworth; J A Walker-Smith; D McCarthy; E J Holborow
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

5.  Coeliac disease with severe hypogammaglobulinaemia.

Authors:  A D Webster; G Slavin; M Shiner; T A Platts-Mills; G L Asherson
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

6.  IgA anti-endomysium antibody. A new immunological marker of dermatitis herpetiformis and coeliac disease.

Authors:  T P Chorzelski; E H Beutner; J Sulej; H Tchorzewska; S Jablonska; V Kumar; A Kapuscinska
Journal:  Br J Dermatol       Date:  1984-10       Impact factor: 9.302

7.  Coeliac disease: a graft-versus-host-like reaction localised to the small bowel wall?

Authors:  G H Neild
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

8.  Binding of wheat gliadin in vitro to reticulum in normal and dermatitis herpetiformis skin.

Authors:  D J Unsworth; G D Johnson; G Haffenden; L Fry; E J Holborow
Journal:  J Invest Dermatol       Date:  1981-02       Impact factor: 8.551

9.  Clinical testing of gliadin fractions in coeliac patients.

Authors:  P J Ciclitira; D J Evans; N L Fagg; E S Lennox; R H Dowling
Journal:  Clin Sci (Lond)       Date:  1984-03       Impact factor: 6.124

10.  Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine.

Authors:  T T MacDonald; J Spencer
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  7 in total

1.  Binding of gliadin to lymphoblastoid, myeloid and epithelial cell lines.

Authors:  M A Farré Castany; P Kocna; H Tlaskalová-Hogenová
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

2.  High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity.

Authors:  Stephanie K Doerner; Edimara S Reis; Elaine S Leung; Justine S Ko; Jason D Heaney; Nathan A Berger; John D Lambris; Joseph H Nadeau
Journal:  Mol Cancer Res       Date:  2016-08-17       Impact factor: 5.852

Review 3.  Immunopathology of gluten-sensitive enteropathy.

Authors:  H Scott; E Nilsen; L M Sollid; K E Lundin; J Rugtveit; O Molberg; E Thorsby; P Brandtzaeg
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Serum mannan-binding lectin levels in patients with celiac disease: an analysis of clinical and autoimmune features.

Authors:  Elisandra Grangeiro de Carvalho; Shirley Ramos da Rosa Utiyama; Lorete Maria da Silva Kotze; Iara Taborda de Messias Reason
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

Review 5.  Cutaneous manifestations in celiac disease.

Authors:  L Abenavoli; I Proietti; L Leggio; A Ferrulli; L Vonghia; R Capizzi; M Rotoli; P L Amerio; G Gasbarrini; G Addolorato
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

6.  Celiac disease and dermatologic manifestations: many skin clue to unfold gluten-sensitive enteropathy.

Authors:  Marzia Caproni; Veronica Bonciolini; Antonietta D'Errico; Emiliano Antiga; Paolo Fabbri
Journal:  Gastroenterol Res Pract       Date:  2012-05-30       Impact factor: 2.260

7.  Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab.

Authors:  Magdalena Riedl; Johannes Hofer; Thomas Giner; Alejandra Rosales; Karsten Häffner; Giacomo D Simonetti; Ulrike Walden; Tanja Maier; Dorothea Heininger; Verena Jeller; Günter Weiss; Lambert van den Heuvel; Lothar B Zimmerhackl; Reinhard Würzner; Therese C Jungraithmayr
Journal:  J Immunol Methods       Date:  2016-05-26       Impact factor: 2.303

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.